Public list Pharma Startups (4732):
Taligen Therapeutics is a development-stage biotechnology company. In January 2011, Taligen Therapeutics was acquired by Alexion Pharmaceuticals. The valuation of Taligen Therapeutics was $111 million.
245 First Street
18th Floor Suite 1830
Massachusetts, United States
|Investor||Investor Type||Location||Participating Rounds|
|Seattle, Washington, United States||Assets Purchased||VLST (Viral Logic Systems Technology) has developed a streamlined and efficient platform that rapidly yields biological therapeutic compositions of matter with a far greater likelihood of success in clinical trials, particularly in autoimmune and inflammatory disorders. The VLST approach combines bioinformatics and proteomics to provide a rapid and rational approach to identifying new targets for the development of biologic therapies. Moreover, the process used to identify targets also provides ...Show all||Login to see details|
|Cambridge, Massachusetts, United States||IPO / Went public||Zafgen is a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity. Beloranib, Zafgen's lead product candidate, is a novel, first-in-class, twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in Prader-Willi syndrome, craniopharyngioma-associated obesity, and severe obesity in the general population. Zafgen was founded in 2005 to explore novel approaches to obesit...Show all||Login to see details|